Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection

Gastroenterology

Volumn 150, Issue 2, 2016, Pages 419-429

  Sulkowski, Mark S ^a,m   Vargas, H E ^m   Di Bisceglie, A M ^m   Kuo, A ^m   Reddy, K R ^m   Lim, Joseph K ^f   Morelli, G ^m   Darling, Jama M ^h   Feld, J ^m   Brown, R S ^m   Frazier, Lynn M ^k   Stewart, Thomas G ^h   Fried, M W ^m   Nelson, D ^m   Jacobson, I M ^m   Afdhal, N ^m   Alam, I ^m   Ben Ari, Z ^m   Bredfeldt, J ^m   Chung, R T ^m   Darling, J ^m   Harlan, W ^m   Dickson, R C ^m   Elbeshbeshy, H A ^m   Everson, G ^m   Fenkel, J M ^m   Galati, J ^m   Gordon, S C ^m   Hassan, M ^m   Hawkins, T N ^m   Hinestrosa, F ^m   Kerr, C A ^m   Kwo, P Y ^m   Levitsky, J ^m   Lim, J ^m   Lok, A S ^m   Mailliard, M ^m   Manns, M P ^m   Muir, A J ^m   O'Leary, J G ^m   Pearlman, B L ^m   Pockros, P ^m   Ramani, A ^m   Reau, N ^m   Schiff, E R ^m   Sherman, K E ^m   Shiffman, M L ^m   Smith, C ^m   Spivey, J R ^m   Sterling, R K ^m   Szabo, G ^m   Terrault, N A ^m   Trautwein, C ^m   Watts, K ^m   Williams, A ^m   Zeuzem, S ^m   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ TORONTO WESTERN HOSPITAL   (Canada)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k Liver Wellness Center   (United States)

^l BETH ISRAEL MEDICAL CENTER   (United States)

^m NONE

more..

Author keywords

Chronic Hepatitis; Direct Acting Agent; NS3 4A Protease Inhibitor; NS5B

Indexed keywords

BILIRUBIN; BOCEPREVIR; CREATININE; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLACK PERSON; BRAIN DISEASE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DEMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INFECTION; INFESTATION; INSOMNIA; JAUNDICE; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PHARMACOLOGICAL PARAMETERS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; MULTICENTER STUDY; NORTH AMERICA; TIME FACTOR; VERY ELDERLY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOMARKERS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SIMEPREVIR; SOFOSBUVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84959473168     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.10.013     Document Type: Article

References (30)

1. D.L. Thomas Global control of hepatitis C: where challenge meets opportunity Nat Med 19 2013 850 858
2. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
3. L.I. Backus, D.B. Boothroyd, B.R. Phillips, and et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
4. B.N. Limketkai, S.H. Mehta, C.G. Sutcliffe, and et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV JAMA 308 2012 370 378
5. A.J. van der Meer, B.J. Veldt, J.J. Feld, and et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
6. J.R. Kramer, F. Kanwal, P. Richardson, and et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325
7. S.H. Mehta, B.L. Genberg, J. Astemborski, and et al. Limited uptake of hepatitis C treatment among injection drug users J Community Health 33 2008 126 133
8. M.T. Melia, A.J. Muir, J. McCone, and et al. Racial differences in hepatitis C treatment eligibility Hepatology 54 2011 70 78
9. T.R. Morgan, M.G. Ghany, H.Y. Kim, and et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
10. E. Lawitz, M.S. Sulkowski, R. Ghalib, and et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
11. L.M. Hagan, M.S. Sulkowski, and R.F. Schinazi Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals Hepatology 60 2014 37 45
12. I.M. Jacobson, G.J. Dore, G.R. Foster, and et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
13. A.I.H.G. Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus Hepatology 2015 62932 62954
14. S.C. Gordon, A.J. Muir, J.K. Lim, and et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET J Hepatol 62 2015 286 293
15. C. Hezode, H. Fontaine, C. Dorival, and et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis Gastroenterology 147 2014 132 142 e4
16. P.A. Harris, R. Taylor, R. Thielke, and et al. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support J Biomed Inform 42 2009 377 381
17. F. Imbert-Bismut, V. Ratziu, L. Pieroni, and et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Lancet 357 2001 1069 1075
18. J. Boursier, J.P. Zarski, L.V. de, and et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography Hepatology 57 2013 1182 1191
19. L. Curtis, B. Hammill, E. Eisenstein, and et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases Med Care 45 Suppl 2 2007 S103 S107
20. H.A. White heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity Econometrica 48 1980 817 838
21. R.R. Andridge, and R.J.A. Little A review of hot deck imputation for survey non-response Int Stat Rev 78 2010 40 64
22. R.J.A. Little, and D. Rubin Statistical analysis with missing data 2nd ed. 2002 John Wiley & Sons
23. Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 (abstract LB14). Program and Abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2015; Vienna, Austria.
24. Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 (abstract LP04). Program and Abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2015; Vienna, Austria.
25. M.P. Manns, J. McCone, M.N. Davis, and et al. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials Liver Int 34 2014 707 719
26. C. Park, S. Jiang, and K.A. Lawson Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis J Clin Pharm Ther 39 2014 14 24
27. OLYSIO® prescribing information. Janssen Therapeutics, Division of Janssen Products, LP. Titusville, NJ: Janssen Therapeutics.
28. J.C. Sullivan, S. De Meyer, D.J. Bartels, and et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin Infect Dis 57 2013 221 229
29. K.P. Romano, A. Ali, C. Aydin, and et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog 8 2012 e1002832
30. M. Manns, P. Marcellin, F. Poordad, and et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426